| Name | Cvs Pharmacy #09205 |
|---|---|
| Organization Name | German Dobson Cvs Llc |
| Location | 802 S Mill Ave, Tempe, Arizona 85281 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (480) 966-6271 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.
By merging more than a decade of atmospheric data from European satellites, scientists have compiled a homogeneous long-term ozone record that allows them to monitor total ozone trends on a global scale - and the findings look promising.
Advanced Cell Diagnostics, Inc. (ACD), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, has been awarded a two-year, $1.4 million grant from National Cancer Institute (NCI) under its SBIR Phase II Program.
Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.
› Verified 7 days ago
| NPI Number | 1437193786 |
| Organization Name | GERMAN DOBSON CVS, L.L.C. |
| Doing Business As | CVS PHARMACY #09205 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 802 S Mill Ave, Tempe, AZ 85281 |
| Phone Number | 480-966-6271 |
News Archive
BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.
By merging more than a decade of atmospheric data from European satellites, scientists have compiled a homogeneous long-term ozone record that allows them to monitor total ozone trends on a global scale - and the findings look promising.
Advanced Cell Diagnostics, Inc. (ACD), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, has been awarded a two-year, $1.4 million grant from National Cancer Institute (NCI) under its SBIR Phase II Program.
Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.
› Verified 7 days ago
| NPI Number | 1811316649 |
| Organization Name | CVS/PHARMACY |
| Doing Business As | CVS PHARMACY 9205 |
| Type | Community/Retail Pharmacy |
| Address | 802 S Mill Ave, Tempe, AZ 85281 |
| Phone Number | 480-966-6271 |
News Archive
BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.
By merging more than a decade of atmospheric data from European satellites, scientists have compiled a homogeneous long-term ozone record that allows them to monitor total ozone trends on a global scale - and the findings look promising.
Advanced Cell Diagnostics, Inc. (ACD), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, has been awarded a two-year, $1.4 million grant from National Cancer Institute (NCI) under its SBIR Phase II Program.
Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.
› Verified 7 days ago
News Archive
BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.
By merging more than a decade of atmospheric data from European satellites, scientists have compiled a homogeneous long-term ozone record that allows them to monitor total ozone trends on a global scale - and the findings look promising.
Advanced Cell Diagnostics, Inc. (ACD), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, has been awarded a two-year, $1.4 million grant from National Cancer Institute (NCI) under its SBIR Phase II Program.
Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.
› Verified 7 days ago
Nielsen And Cyment, Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2403 W Huntington Dr, Tempe, Arizona 85282 Phone: (480) 675-9122 | |
Preferred Homecare Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3280 S Country Club Way, Tempe, Arizona 85282 Phone: (480) 505-0038 | |
Cvs Pharmacy #09205 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 802 S Mill Ave, Tempe, Arizona 85281 Phone: (480) 966-6271 | |
Cvs Pharmacy #05950 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 855 E Elliot Rd, Tempe, Arizona 85284 Phone: (480) 456-3602 | |
Cvs Pharmacy #07078 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3303 S Rural Rd, Tempe, Arizona 85282 Phone: (480) 345-6328 |